Conversely, CDKN2A-MUT patients exhibited longer OS than CDKN2A-WT patients with metastatic disease (HR, 0.59; 95% CI, 0.40–0.87; Fig. 3H). This evidence concerns the gene CDKN2A and metastatic neoplasm.